PDCD1 and posterior cortical atrophy: In addition, a phase-II study is assessing the antigen-specific immune response of sipuleucel-T vaccine therapy with or without 223Ra (50 kBq/kg) (NCT02463799), whereas another phase-II study is investigating the combination of 223Ra plus the anti-PD-1 checkpoint inhibitor pembrolizumab as a possible treatment for castration-resistant PCa (NCT03093428).